Ratings Zwipe

Equities

Market Closed - Oslo Bors Other stock markets 15:45:00 29/04/2024 BST			5-day change	1st Jan Change
0.55 ^NOK	-7.72%		-14.06%	-15.77%

03-27	SCAP and Zwipe A.S. Partner to Bring Biometric Access Cards in France	CI
02-22	Transcript : Zwipe AS, H2 2023 Earnings Call, Feb 22, 2024

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's enterprise value to sales, at 5.62 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ZWIPE	-15.77%	5.36M		-
ORBBEC INC.	-22.22%	1.55B		-
PAPILON SAVUNMA TEKNOLOJI VE TICARET	+171.03%	161M	-	-
SUPREMA INC.	+17.51%	120M		-
NEXT BIOMETRICS GROUP ASA	+22.54%	80.39M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality